XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
Key Highlights
- ➤Japan Patent Office allowed six claims supporting XRx-101 for acute kidney injury
- ➤Japanese patent registration could provide protection through March 15, 2041
- ➤XORTX patent portfolio reaches seven granted or allowed patents and 14 pending applications
- ➤XORTX has no partnering or licensing agreement for XRx-101
Expert Statements
Allen Davidoff, Co-Chief Executive Officer of XORTX
“This decision is expected to provide XRx-101 with its first patent protection in Japan, one of the world’s largest pharmaceutical markets, and the allowed claims are directed to the central premise of the program – that inhibiting xanthine oxidase may attenuate injurious, rapid increases in uric acid and the acute kidney injury that can follow serious respiratory viral infection”
Allen Davidoff, Co-Chief Executive Officer of XORTX
“Expanding our xanthine oxidase inhibitor patent estate into Japan strengthens the intellectual property position of that platform, which also includes XORLO™ for gout, and broadens the options available to the Company as it evaluates potential partnering opportunities for programs beyond XRx-026.”
CALGARY, Alberta, Nov. 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that the Japan Patent Office (the “JPO”) has issued a Decision to Grant a Patent for Japanese Patent Application No. 2022-556140, entitled “Compositions, Formulations, and Containers” (the “Japanese Patent”). Once registered, the Japanese Patent will support the Company’s XRx-101 program for acute kidney injury and other acute organ injury associated with respiratory virus infections, and will be the Company’s first patent in Japan directed to its xanthine oxidase inhibitor programs.
A Decision to Grant is the JPO’s determination that the examiner has found no reasons to refuse the application. The Japanese Patent will issue upon payment of the registration fee and registration by the JPO. The application is the Japanese national phase of International Application No. PCT/IB2021/000238 and claims priority to U.S. Provisional Application No. 62/989,879, filed March 15, 2020. The six allowed claims are directed to pharmaceutical compositions comprising a xanthine oxidase inhibitor, including oxypurinol, for the treatment or prevention of acute kidney injury and other health consequences associated with viral infection. Under Japanese patent practice, therapeutic uses are generally protected through composition claims. Once registered, the Japanese Patent is expected to remain in force until March 15, 2041, subject to the payment of annuity fees and excluding any patent term extension that may become available
Get started
Create a free account to read the full story.